SIC
ASND icon

SJS Investment Consulting’s Ascendis Pharma A/S ASND Stock Holding History

SJS Investment Consulting’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$10K Hold
86
– – ﹤0.01% 384
2021
Q4 		$12K Buy
+86
New +$12.8K ﹤0.01% 346

Other funds holding ASND

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SJS Investment Consulting's ASND Position: Q1 2022 in Review

SJS Investment Consulting held its Ascendis Pharma A/S (ASND) position steady in Q1 2022 at 86 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #384.

SJS Investment Consulting first reported a position in ASND in Q4 2021 and has held it in 2 quarters since. The position peaked at $12K in Q4 2021. 178 funds tracked by Wall St. Rank hold ASND as of Q1 2022.

  • SJS Investment Consulting held 86 shares of Ascendis Pharma A/S worth $10K as of Q1 2022.
  • SJS Investment Consulting left its Ascendis Pharma A/S share count unchanged in Q1 2022.
  • Ascendis Pharma A/S made up ﹤0.01% of SJS Investment Consulting's portfolio in Q1 2022, its #384 holding.
  • SJS Investment Consulting first reported a position in Ascendis Pharma A/S in Q4 2021 and has held it in 2 quarters since.
  • SJS Investment Consulting's Ascendis Pharma A/S position peaked at $12K in Q4 2021.
  • 178 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2022.

Based on SJS Investment Consulting's 13F filing for Q1 2022, filed 5 May 2022.